Full-Time

Investigator I / II

Posted on 10/25/2024

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

No salary listed

Mid, Senior

Bridgewater Township, NJ, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Google Cloud Platform
Requirements
  • A minimum of a Bachelor’s degree in engineering or related field or equivalent experience required. Advanced degree preferred.
  • A minimum of 5 years of operations or quality Assurance experience within a cGMP environment in the biotech/biopharma industry and Cell/Gene Therapy cGMP manufacturing experience preferred
  • Support writing of SOPs for Manufacturing and Quality Risk Assessments for existing and new/changed processes.
  • Ability to work independently and successfully, prioritize and manage multiple tasks simultaneously, integrate cross-functional issues and balance competing priorities effectively. Must be able to manage shifting priorities to meet critical deadlines in a fast paced and dynamic, growing environment.
  • Advanced knowledge in cGMP.
  • Ability to interpret results and situations and articulate recommendations for resolution.
  • Excellent verbal and written communication skills.
  • Experience with electronic document management systems.
  • Drive CAPA closures and follow up in Effectiveness checks.
  • An ability to build strong partnerships and effectively integrate with external collaborators to drive projects/programs forward in a matrixed environment.
  • Language: English
Responsibilities
  • Lead cross functional investigations independently from end to end.
  • Ensure thorough root cause analysis, impact assessment, and CAPA/EC determination.
  • Serves as Subject Matter Expert (SME) in preparation for and during internal and external regulatory audits (including FDA, EMEA).
  • Support coordination of data collection and trend analysis as requested by QA and Regulatory Affairs including the annual report and continued process verification (CPV)
  • Recognize and act on potential compliance issues and opportunities for process changes/improvement.
  • Provide technical expertise in the Technical Operations group, process knowledge of the cell and gene therapy manufacturing, including but not limited to deviations (Quality Issues), investigations, CAPA management.
  • Work cross functionally with SME's and Quality to ensure robustness of investigations, as well as accuracy and ensuring compliance.
  • Must have a strong knowledge and experience with cGMP, GCP, GLP, Quality and Compliance.
  • Must have strong authorship and be able to critically review investigations, interpret results and generate technical conclusion consistent with Quality risk management principles.
  • Must be able to effectively prepare communications with interpretation of data analysis and potential problems to management and the group with clarity and a high level of accuracy.
  • Must provide guidance to other associates in the interpretation of technical issues across an interdisciplinary team.
  • Must be action-oriented and customer-focused, building relationships, problem solving, planning and organizing, conflict management, resource allocation, coaching others and analytical thinking. Confident in making decisions for minor issues.
  • Must be nimble and an agile learner able to assimilate large amount of data quickly and simplify to coherent story to support an investigation.
  • Intermediate to advanced ability to interpret results and situations and articulate recommendations for resolution.
  • Teamwork and ability to work effectively across functional groups and teams to ensure requirements are met. Must be self-motivated and driven to independently seek out answers.
  • Willing to work on shift as required.
Desired Qualifications
  • Advanced degree preferred.
  • Cell/Gene Therapy cGMP manufacturing experience preferred

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates within the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Multiply Labs could enhance manufacturing efficiency through automation.
  • European Commission's approval of CARVYKTI® expands market reach in multiple myeloma treatment.
  • New R&D facility in Philadelphia may lead to breakthroughs in next-generation cell therapies.

What critics are saying

  • Competition from Amgen's Imdelltra may impact market share in oncology.
  • Expansion into Philadelphia R&D facility could strain financial resources if mismanaged.
  • Dependency on MaxCyte's technology poses risks if MaxCyte faces operational issues.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective treatments.
  • Legend Biotech's business model includes discovery, development, and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Yellow Brick Road
Mar 3rd, 2025
YB new stock pitches (Mon, Mar 3)

Legend Biotech Corporation (LEGN) is developing a promising CAR-T cancer drug in partnership with Johnson & Johnson.

ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.

Global Culture Review
Oct 3rd, 2024
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.

INACTIVE